9 recruiting, 7 completed, 3 not yet recruiting, 2 active not recruiting. 22 Phase 2, 10 Phase 1, 1 Phase 3.
Follow Dizal Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) Birelentinib, Rituximab, Cyclophosphamid - Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 / Phase 3 | Not yet recruiting | Dizal Pharmaceuticals | 880 | 2026-09-01 | 2026-08-05 |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) GW5282 combined with Golidocitinib, Conventional CHOP regimen - T-cell Lymphomas | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2026-04-15 | 2026-10-22 |
| A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors GW5282 - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 203 | 2026-01-29 | 2026-02-11 |
| A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) DZD8586 dose level 1, DZD8586 dose level 2, DZD8586 dose level 3 - Immune Thrombocytopenia (ITP) | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2026-01-15 | 2026-01-22 |
| A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) DZD8586, Venetoclax - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Dizal Pharmaceuticals | 66 | 2025-09-22 | 2026-06-22 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) DZD8586+R-CHOP, DZD8586+R-GemOx, DZD8586+BR - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 150 | 2025-08-19 | 2026-04-01 |
| Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8) DZD6008, Sunvozertinib, Osimertinib - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 220 | 2025-07-30 | 2026-10-23 |
| DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) DZD6008, Pemetrexed, Carboplatin - Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Dizal Pharmaceuticals | 180 | 2025-07-16 | 2026-08-31 |
| DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) DZD8586 - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Recruiting | Dizal Pharmaceuticals | 155 | 2024-04-29 | 2026-06-02 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) DZD8586 - Diffuse Large B Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 59 | 2024-03-13 | 2026-08-04 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) Golidocitinib, Sintilimab, platinum doublet chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2024-01-01 | 2024-01-10 |
| A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) DZD9008+AZD4205 - Non-small Cell Lung Cancer | Phase 2 | Completed | Dizal Pharmaceuticals | 30 | 2023-06-01 | 2026-10-22 |
| DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) DZD9008 plus Bevacizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | Dizal Pharmaceuticals | 60 | 2023-02-15 | 2025-06-19 |
| A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) DZD8586 - Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Dizal Pharmaceuticals | 17 | 2022-06-01 | 2025-02-21 |
| AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) AZD4205 - Peripheral T Cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 57 | 2022-05-31 | 2025-12-24 |
| AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) AZD4205 - Peripheral T-cell Lymphoma | Phase 2 | Completed | Dizal Pharmaceuticals | 48 | 2022-03-17 | 2025-07-04 |
| Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) DZD9008 - Non-Hodgkin's B-cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | Dizal Pharmaceuticals | 2021-08-01 | 2025-02-25 | |
| Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) Sunvozertinib - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | Dizal Pharmaceuticals | 104 | 2021-07-19 | 2024-12-30 |
| Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) golidocitinib - Relapsed or Refractory Peripheral T Cell Lymphoma | Phase 1 / Phase 2 | Completed | Dizal Pharmaceuticals | 171 | 2019-09-10 | 2025-04-04 |
Showing 20 of 22. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (8) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, T-Cell, Peripheral (3) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Large Granular Lymphocytic (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Purpura, Thrombocytopenic, Idiopathic (1) · Recurrence (1) · Sezary Syndrome (1)
Bevacizumab (1) · Carboplatin (1) · Cyclophosphamide (1) · Docetaxel (1) · Doxorubicin (1) · Pemetrexed (1) · Prednisone (1) · Rituximab (1) · Vincristine (1) · osimertinib (1) · sintilimab (1) · venetoclax (1)
China (20) · Australia (3) · United States (3) · South Korea (2) · Argentina (1) · Canada (1) · Chile (1) · France (1) · Italy (1) · Japan (1) · Malaysia (1) · Spain (1) · Taiwan (1)
Jianyong Li (2) · Mengzhao Wang (2) · Anne Zhang (1) · Jie Jin (1) · Jie Wang, MD,PhD (1) · Lugui Qiu (1) · Neha Mehta-Shah, MD (1) · Pamela Yang, MD, PhD (1) · Won Seog Kim, PhD (1) · Yuqin Song (1)
PMID 38092009, PMID 38101437, PMID 38924456, PMID 40782807, PMID 40923280